James N. Kochenderfer, MD, Experimental Transplantation and Immunology Branch, National Cancer Institute in Bethesda, MD, discusses the B-cell antigen CD19 and its role in chemotherapy-resistant B-cell malignancies. At the 53rd Annual Meeting of the American Society of Hematology, held at the San Diego Convention Center, Kochenderfer presented data on 8 patients treated with an anti-CD19 chimeric antigen receptor. While the agent did cause some toxicity in patients, it was able to eliminate targeted cells.

>>>Return to the main conference coverage page.

Videos

Dr. James Kochenderfer from the National Cancer Institute Discusses the B-cell Antigen CD19

James N. Kochenderfer, MD

Articles

Dr. Kochenderfer Discusses the B-cell Antigen CD19